Vernon Harvey

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 551 citations

Breast Oncology, Health Sciences, Medicine +9

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

David Cameron, Julia Brown, Rebecca Dent et al. · The Lancet Oncology · 2013 · 432 citations

Adjuvant Bevacizumab-containing Therapy, Breast Oncology, Medicine +7

Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule

José Baselga, Xavier Carbonell, Noel-Jaime Castañeda-Soto et al. · Journal of Clinical Oncology · 2005 · 425 citations · Full text

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

Andreas Schneeweiß, Stephen Chia, Tamas Hickish et al. · European Journal of Cancer · 2017 · 270 citations

Breast Oncology, Oncology, Safety Study +7